ADMA BIOLOGICS INC
ADMANASDAQTrading Snapshot
- Day Range
- $9.84 – $10.11
- 52-Week Range
- $7.21 – $20.46
- Volume
- $4.85B
- Avg Volume
- $5.79B
- Shares Outstanding
- 231.8M
- Next Earnings
- Dec 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $510M
- Last Q Revenue
- $124M
- P/E Ratio
- 14.1
- P/S Ratio
- 4.6x
- EPS (TTM)
- $0.74
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −0.8%
Why Investors Own ADMA
- ✓High-growth profile — revenue up -4.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 74% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ADMA BIOLOGICS INC
ADMA
StockOtter · stockotter.spaceAbout ADMA BIOLOGICS INC
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
ADMA BIOLOGICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ADMA price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ADMA BIOLOGICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.